AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33569703 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression
Number of subjects: 62
Study 33569703 — intervention group
Group type: COMPARATOR
Intervention: Cytomorphological evaluation of bone marrow aspirate
Number of subjects: 62
Study 33569981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial information regarding patients' subclinical atherosclerosis
Number of subjects: 15
Study 33569981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial information and written information regarding atherosclerosis and CVD risk
Number of subjects: 15
Study 33569981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial information about carotid ultrasound results
Number of subjects: 15
Study 33569983 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study 33570247 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PARP inhibitor (PARPi) and EZH2 inhibitor
Number of subjects: 0
Study 33570423 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Motor-Driven Endoscopic Ablation System
Number of subjects: 0
Study 33570583 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (specific micronutrients not detailed)
Number of subjects: 0
Study 33570583 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient fortification programs (not detailed)
Number of subjects: 0
Study 33570641 — intervention group
Group type: EXPERIMENTAL
Intervention: DICER1 carriers
Number of subjects: 0
Study 33570641 — intervention group
Group type: COMPARATOR
Intervention: Family controls
Number of subjects: 0
Study 33570641 — intervention group
Group type: EXPERIMENTAL
Intervention: DICER1 carriers and family controls
Number of subjects: 0
Study 33571163 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 gene-edited CD4+ T cells (infused 10 billion cells)
Number of subjects: 14
Study 33571163 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 gene-edited CD4+ T cells
Number of subjects: 14
Study 33571166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 0
Study 33571166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 33571166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone and mirabegron
Number of subjects: 0
Study 33571166 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 0
Study 33571215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Hypertension (OHT)
Number of subjects: 180
Study 33571215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-perimetric primary open-angle glaucoma (pre-POAG)
Number of subjects: 180
Study 33571215 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 180
Study 33571215 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (OHT, pre-POAG, controls)
Number of subjects: 180
Study 33571265 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face individual semi-structured interviews with GPs
Number of subjects: 20
Study 33571265 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilisation of diagnostic testing
Number of subjects: 20
Study 33571265 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions on the introduction of rapid point-of-care tests
Number of subjects: 20
Study 33571362 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily growth hormone treatment
Number of subjects: 37702
Study 33571450 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in children
Number of subjects: 688
Study 33571450 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in daycare centre staff
Number of subjects: 688
Study 33571450 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 seroprevalence in comparator group
Number of subjects: 688
Study 33571450 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated SARS-CoV-2 infection in children
Number of subjects: 688
Study 33571450 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated SARS-CoV-2 infection in daycare centre staff
Number of subjects: 688
Study 33571450 — intervention group
Group type: COMPARATOR
Intervention: Estimated SARS-CoV-2 infection in comparator group
Number of subjects: 688
Study 33571450 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis of seropositive children exposure
Number of subjects: 688
Study 33571520 — intervention group
Group type: EXPERIMENTAL
Intervention: Neogenin expression in DIPG tumors, specific dosage and duration not available
Number of subjects: 0
Study 33571930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain in PLWD
Number of subjects: 272
Study 33571930 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver upset with NPS
Number of subjects: 272
Study 33573594 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led exercise program, twice a week for 12 weeks, led by a trained leader of the same age.
Number of subjects: 31
Study 33573648 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term residential exposure to air pollution (fine particulate matter, PM)
Number of subjects: 133
Study 33573648 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential access to neighborhood greenspaces
Number of subjects: 133
Study 33573693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction combined with a Mediterranean diet (IER + MED)
Number of subjects: 59
Study 33573693 — intervention group
Group type: COMPARATOR
Intervention: Dietary Approaches to Stop Hypertension (DASH) diet
Number of subjects: 59
Study 33573694 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) parenting program for 19 weeks
Number of subjects: 102
Study 33573694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study 33573885 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 prevention strategies in long-term care facilities
Number of subjects: 0
Study 33573885 — intervention group
Group type: EXPERIMENTAL
Intervention: GeroCovid Observational Study
Number of subjects: 0
Study 33573928 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 132
Study 33574022 — intervention group
Group type: EXPERIMENTAL
Intervention: EF1 above the median in asymptomatic patients
Number of subjects: 202
Study 33574022 — intervention group
Group type: EXPERIMENTAL
Intervention: EF1 above the median in patients with discordant AS
Number of subjects: 202
Study 33574078 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gene RNA model (TB22)
Number of subjects: 222
Study 33574140 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome composition analysis using 16S ribosomal RNA sequencing.
Number of subjects: 0
Study 33574140 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of arterial stiffness using cf-PWV, CAVI, ba-PWV, and Ankle-Brachial Index.
Number of subjects: 0
Study 33574140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle assessment through food frequency questionnaire, Mediterranean diet adherence, and IPAQ.
Number of subjects: 0
Study 33574140 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition evaluation by bioimpedance.
Number of subjects: 0
Study 33574446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT) with a dose of 50 Gy (25 fractions of 2 Gy over 5 weeks)
Number of subjects: 288
Study 33574446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 288
Study 33574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Early re-exacerbation (1-90 days)
Number of subjects: 1420
Study 33574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Late re-exacerbation (91-180 days)
Number of subjects: 1420
Study 33574663 — intervention group
Group type: EXPERIMENTAL
Intervention: No re-exacerbation within 180 days
Number of subjects: 1420
Study 33574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of re-exacerbation
Number of subjects: 1420
Study 33574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged AECOPDs
Number of subjects: 1420
Study 33574699 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit (with Fitbit device)
Number of subjects: 82
Study 33574699 — intervention group
Group type: COMPARATOR
Intervention: GetActive (without Fitbit device)
Number of subjects: 82
Study 33574792 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting for symptomatic intracranial artery stenosis
Number of subjects: 0
Study 33574900 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) combined with cisplatin-based chemoradiation (CCRT)
Number of subjects: 10
Study 33574913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin combined with metformin (Sig)
Number of subjects: 168
Study 33574913 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy (Ins)
Number of subjects: 168
Study 33575025 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPECTS assessment
Number of subjects: 150
Study 33575025 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPECTS cutoff value
Number of subjects: 150
Study 33575322 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated-interferon (PEG-IFN)
Number of subjects: 0
Study 33575322 — intervention group
Group type: COMPARATOR
Intervention: Entecavir therapy
Number of subjects: 0
Study 33575428 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with HIV
Number of subjects: 0
Study 33575428 — intervention group
Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 0
Study 33575683 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-counseling intervention
Number of subjects: 0
Study 33575683 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33575971 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (positive psychology-motivational interviewing)
Number of subjects: 52
Study 33575971 — intervention group
Group type: EXPERIMENTAL
Intervention: Early increase cutoffs of 500 and 2000 steps
Number of subjects: 52
Study 33575971 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in early steps
Number of subjects: 52
Study 33576064 — intervention group
Group type: EXPERIMENTAL
Intervention: Smarthealth technology
Number of subjects: 30
Study 33576249 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 33576249 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 33576388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in LFLG-AS patients
Number of subjects: 202
Study 33576388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in LFLG-AS patients with high likelihood of true-severe AS
Number of subjects: 202
Study 33576388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in LFLG-AS patients with intermediate likelihood of true-severe AS
Number of subjects: 202
Study 33576388 — intervention group
Group type: COMPARATOR
Intervention: High-gradient aortic stenosis (AS) patients
Number of subjects: 202
Study 33576388 — intervention group
Group type: EXPERIMENTAL
Intervention: LFLG-AS patients with high likelihood of true-severe AS
Number of subjects: 202
Study 33576388 — intervention group
Group type: EXPERIMENTAL
Intervention: LFLG-AS patients with intermediate likelihood of true-severe AS
Number of subjects: 202
Study 33576388 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria for treatment futility
Number of subjects: 202
Study 33576412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) using untargeted machine learning for predicting CV mortality.
Number of subjects: 214
Study 33576412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) for predicting all-cause mortality.
Number of subjects: 214
Study 33576546 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 94
Study 33576546 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 94
Study 33577377 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified geriatric assessment (sGA)
Number of subjects: 1163
Study 33577377 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly Prognostic Index (EPI)
Number of subjects: 1163
Study 33577377 — intervention group
Group type: EXPERIMENTAL
Intervention: original geriatric assessment (oGA)
Number of subjects: 1163
Study 33577377 — intervention group
Group type: EXPERIMENTAL
Intervention: overall survival (OS)
Number of subjects: 1163
Study 33577756 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropulse trans-scleral laser therapy (mTLT)
Number of subjects: 52
Study 33577985 — intervention group
Group type: COMPARATOR
Intervention: Liquid chromatography-mass spectrometry (LC-MS) metabolomics analyses
Number of subjects: 100
Study 33578396 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-IMS for SARS-CoV-2 detection
Number of subjects: 75
Study 33578396 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-IMS for influenza-A detection
Number of subjects: 75
Study 33578396 — intervention group
Group type: COMPARATOR
Intervention: Control group (44 patients)
Number of subjects: 75
Study 33578396 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC-IMS
Number of subjects: 75
Study 33578615 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated transcranial magnetic stimulation (TMS) priming with transcranial direct current stimulation (tDCS) combined with constraint-induced movement therapy (CIMT)
Number of subjects: 0
Study 33578615 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with constraint-induced movement therapy (CIMT)
Number of subjects: 0
Study 33579196 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy surveillance
Number of subjects: 234
Study 33579196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 234
Study 33579196 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 234
Study 33579196 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum levels in blood and urine
Number of subjects: 234
Study 33579197 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/TT genotype (minor T allele of rs3918242)
Number of subjects: 498
Study 33579197 — intervention group
Group type: COMPARATOR
Intervention: rs3918242
Number of subjects: 498
Study 33579213 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless physiologic monitoring system
Number of subjects: 0
Study 33579213 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (manual vital sign measurement when clinically indicated)
Number of subjects: 0
Study 33579242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile technology-based intervention informed by behavioral economics
Number of subjects: 41
Study 33579332 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT) for 16 weeks, consisting of weekly therapy sessions (family/individual or both) according to the treatment manual.
Number of subjects: 60
Study 33579332 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for 16 weeks, not monitored.
Number of subjects: 60
Study 33579332 — intervention group
Group type: EXPERIMENTAL
Intervention: ABFT and TAU both assessed using the Beck Depression Inventory-II (BDI-II) for self-reported depressive symptoms at multiple time points (baseline, and after 4, 6, 8, 10, 12, 14, and 16 weeks).
Number of subjects: 60
Study 33579338 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional preoperative planning
Number of subjects: 63
Study 33579396 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD preventive care in HIV specialty clinics
Number of subjects: 37
Study 33579396 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV care providers' roles in CVD prevention
Number of subjects: 37
Study 33579396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level interventions for HIV providers
Number of subjects: 37
Study 33579579 — intervention group
Group type: EXPERIMENTAL
Intervention: No symptoms reported
Number of subjects: 6680
Study 33579579 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu-like symptoms cluster
Number of subjects: 6680
Study 33579579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined generic and flu-like symptoms cluster
Number of subjects: 6680
Study 33579579 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste/smell disorders
Number of subjects: 6680
Study 33579739 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab and nab-paclitaxel (specific dosage and duration not mentioned)
Number of subjects: 0
Study 33579739 — intervention group
Group type: COMPARATOR
Intervention: Placebo comparator arm of the IMpassion130 trial
Number of subjects: 0
Study 33579774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFOT)
Number of subjects: 330
Study 33579774 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) alternating with HFOT
Number of subjects: 330
Study 33579774 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV alternating with standard oxygen
Number of subjects: 330
Study 33579966 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication intervention engaging family care partners
Number of subjects: 118
Study 33579966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients whose care partners logged into MyChart
Number of subjects: 118
Study 33580032 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 22
Study 33580032 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 22
Study 33580261 — intervention group
Group type: EXPERIMENTAL
Intervention: High amounts of SARS-CoV-2 virus (indicated by PCR Ct value)
Number of subjects: 9449
Study 33580261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amounts of SARS-CoV-2 virus
Number of subjects: 9449
Study 33580261 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology-positive subjects
Number of subjects: 9449
Study 33580363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 12
Study 33580495 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectome ab interno trabeculotomy combined with cataract extraction (phaco-AIT)
Number of subjects: 19
Study 33580495 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C combined with cataract extraction (phaco-Trab)
Number of subjects: 19
Study 33580657 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms at admission
Number of subjects: 154
Study 33580657 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in insomnia symptoms from admission to 3 months
Number of subjects: 154
Study 33580657 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms at 3 months
Number of subjects: 154
Study 33580776 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for PCS
Number of subjects: 665
Study 33580779 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity troponin T (hs-cTnT) reference
Number of subjects: 1042
Study 33580779 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of microRNAs (miR-122, miR-133, and miR-134)
Number of subjects: 1042
Study 33580779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of miRNA panel and hs-cTnT reference
Number of subjects: 1042
Study 33580779 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNAs
Number of subjects: 1042
Study 33580779 — intervention group
Group type: EXPERIMENTAL
Intervention: Single miRNAs
Number of subjects: 1042
Study 33580980 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and venetoclax
Number of subjects: 0
Study 33581080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor-ivacaftor (oral tezacaftor 100 mg once daily and oral ivacaftor 150 mg once every 12 hours for up to 96 weeks)
Number of subjects: 1042
Study 33581080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor-ivacaftor
Number of subjects: 1042
Study 33581302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting-through group (46 patients)
Number of subjects: 78
Study 33581302 — intervention group
Group type: COMPARATOR
Intervention: No cutting-through group (32 patients)
Number of subjects: 78
Study 33581379 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rTMS course (arTMS) of 6 sessions/day over 5 days (30 total) followed by tapering course of daily sessions (up to 25)
Number of subjects: 48
Study 33581379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) 1 Hz stimulation protocol (360 pulses per session)
Number of subjects: 48
Study 33581722 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Aids (HA)
Number of subjects: 100
Study 33581739 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical activity, nutrition, and palliative symptom management intervention
Number of subjects: 23
Study 33581739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise classes
Number of subjects: 23
Study 33581976 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 402
Study 33581976 — intervention group
Group type: EXPERIMENTAL
Intervention: T3-4 lesions
Number of subjects: 402
Study 33581976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic lymph node involvement
Number of subjects: 402
Study 33581976 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aortic lymph node involvement
Number of subjects: 402
Study 33581976 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-2 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis
Number of subjects: 402
Study 33581976 — intervention group
Group type: EXPERIMENTAL
Intervention: T3-4 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis
Number of subjects: 402
Study 33582086 — intervention group
Group type: EXPERIMENTAL
Intervention: Online assessment of regurgitation using videodensitometry
Number of subjects: 100
Study 33582086 — intervention group
Group type: COMPARATOR
Intervention: Offline assessment by core laboratory
Number of subjects: 100
Study 33582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-arterial chemoembolization
Number of subjects: 34000
Study 33582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy
Number of subjects: 34000